GlassScriptPhysician profile
Lisa K Sprague
NPI 1346627536
$4,484.73
in general payments reported to CMS, 2019-2025
29 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,367 · 2022: $703 · 2023: $818 · 2024: $1,064 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $809.44 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $545.00 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $478.52 | 2021-2025 | Repatha, Repatha, Prolia |
| Pfizer INC. | $311.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $239.65 | 2021-2025 | Farxiga, Airsupra, Brilinta |
| Novartis Pharmaceuticals Corporation | $220.52 | 2021-2025 | |
| Astellas Pharma US INC | $201.35 | 2021-2024 | Veozah |
| Abbvie INC. | $186.32 | 2021-2024 | |
| Esperion Therapeutics, INC. | $167.91 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $157.76 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.64 | 2021-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $133.43 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Abiomed | $128.84 | 2024-2025 | Impella |
| Neurocrine Biosciences, INC. | $120.85 | 2023-2024 | Ingrezza, Ongentys |
| Glaxosmithkline, LLC. | $97.68 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $80.58 | 2021 | |
| Merck Sharp & Dohme LLC | $79.67 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $73.38 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $57.64 | 2024 | Gvoke Hypopen |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.98 | 2025 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $40.02 | 2021-2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $31.04 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $29.44 | 2021 | |
| Scpharmaceuticals INC. | $20.06 | 2025 | |
| Ucb, INC. | $19.53 | 2021 | |
| Medtronic, INC. | $15.49 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.60 | 2021 | |
| Boston Scientific Corporation | $12.05 | 2022 | |
| Sumitomo Pharma America, INC. | $6.00 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Sprague listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.